Price
Target price
€29.20
€29.20
-1.340%
-0.4
-1.340%
€35.33
13.08.26 / Tradegate
WKN: A1W2RM / Symbol: AGIO / Name: Agios / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Agios Pharmaceuticals Inc. Stock
A loss of -1.340% shows a downward development for Agios Pharmaceuticals Inc..
The stock is an absolute favorite of our community with 21 Buy predictions and no Sell predictions.
With a target price of 35 € there is a slightly positive potential of 19.86% for Agios Pharmaceuticals Inc. compared to the current price of 29.2 €.
So far the community has only identified positive things for Agios Pharmaceuticals Inc. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Agios Pharmaceuticals Inc. in the next few years
Pros
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
B****
Cons
?
M***** P*******
?
C******** o* t** e**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Agios Pharmaceuticals Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Agios Pharmaceuticals Inc. | -1.340% | 2.817% | -16.092% | -7.006% | 25.862% | 21.667% | -21.188% |
| Ionis Pharmaceuticals Inc. | 0.780% | 7.292% | 8.284% | 38.366% | -24.220% | 44.056% | 58.462% |
| United Therapeutics | -0.110% | 0.359% | -4.315% | 66.320% | 4.821% | 112.074% | 163.471% |
| Novocure Ltd | -1.390% | -2.680% | 6.509% | 43.726% | 31.363% | -48.209% | -86.735% |
Comments
Agios Pharmaceuticals (AGIO) had its price target lowered by Truist Financial Corporation from $41.00 to $39.00. They now have a "buy" rating on the stock.
Show more
Ratings data for AGIO provided by MarketBeat
Agios Pharmaceuticals (AGIO) had its price target raised by HC Wainwright from $52.00 to $55.00. They now have a "buy" rating on the stock.
Show more
Ratings data for AGIO provided by MarketBeat
Agios Pharmaceuticals (AGIO) had its price target lowered by HC Wainwright from $54.00 to $52.00. They now have a "buy" rating on the stock.
Show more
Ratings data for AGIO provided by MarketBeat
News
Agios Pharmaceuticals Q2 Earnings Call Highlights
Key Points
- Interested in Agios Pharmaceuticals, Inc.? Here are five stocks we like better.
- Mitapivat revenue reached $44.7 million in Q2 2026, while Agios reported a $100.7 million net loss
Here's Why Shares in Novo Nordisk Rival, Agios Pharmaceutical, Soared This Week
Agios Pharmaceuticals (NASDAQ: AGIO) stock rose by 13.8% during the week through Friday morning. It's a move driven by the Food and Drug Administration's (FDA) announcement that it would grant
Here's Why Agios Pharmaceuticals Stock Soared Today (Hint: It's FDA-Related)
Shares in Agios Pharmaceuticals (NASDAQ: AGIO) were higher by more than 14% as of 11 a.m this morning. The move comes after a very positive development from the Food and Drug Administration (FDA) on